Cargando…
Clinical Use of the Low-Molecular-Weight Heparins in Cancer Patients: Focus on the Improved Patient Outcomes
Patients with malignant neoplastic diseases represent a high-risk population relative to thromboembolic disease. With the advent of improved and accessible diagnostic technology, for example, ultrasound and/or spiral CT scans, timely diagnosis of venous thromboembolic events (VTE) is readily accompl...
Autores principales: | Chao, Bo H., Lepeak, Lisa, Leal, Ticiana, Robins, H. Ian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195390/ https://www.ncbi.nlm.nih.gov/pubmed/22084664 http://dx.doi.org/10.1155/2011/530183 |
Ejemplares similares
-
Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014) -
Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes
por: Akhtar, Fahad, et al.
Publicado: (2018) -
The potential benefits of low-molecular-weight heparins in cancer patients
por: Robert, Francisco
Publicado: (2010) -
Use of low-molecular-weight heparin in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020) -
Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)